


May 15-17, 2024
Cardiovascular
Development
and Regeneration
Conference

Hotel Bonaventure



Weinstein
2024 | Montréal, Qc.



WELCOME TO THE 28TH WEINSTEIN CONFERENCE

MAY 15-17, 2024

Established in 1994, the Weinstein Cardiovascular Development and Regeneration Conference has strongly contributed to guide and shape cardiovascular research from development and congenital heart defects (CHDs), to heart failure and cardiac regeneration. CHD and acquired cardiovascular diseases are amongst the most commonly diagnosed and the number one cause of mortality worldwide. The Weinstein conference provides a platform to discuss cardiovascular development, origins of CHD, and potential cardiac regeneration approaches for newborn, pediatric, and adult patients with cardiovascular diseases.

Weinstein Conferences have **more than 300 participants**, and the meeting is unique in several ways. First, it is one of the few scientific meetings dedicated to the development of **early career scientists**. Second, the meeting is organized and funded solely by academic researchers. Third, there is great emphasis to present **state-of-the-art technologies** and **unpublished scientific findings**.

Conference Location

Hotel Bonaventure

900, rue de la Gauchetière O
Montréal (Québec) H5A 1E4

Platform Sessions

- Regeneration
- Cardiac conduction and electrophysiology
- Cell culture and stem cells
- Congenital heart disease models
- Generics and epigenetics
- Single ventricle defects
- Human genetics and tissue engineering
- Cardiomyocyte biology and cell fate
- Valvular and vascular biology
- Heart fields and morphogenesis

2024 Local Organizing Committee



Gregor Andelfinger, Chair

CHU Sainte-Justine Research Center
Montréal, Canada

Alexandre Dubrac

CHU Sainte-Justine Research Center
Montréal, Canada



Rubén Marín-Juez

CHU Sainte-Justine Research Center
Montréal, Canada

Ian Scott

The Hospital for Sick Children
Toronto, Canada



Piet van Vliet

CHU Sainte Justine Research Center
Montréal, Canada

A WORD FROM YOUR COMMITTEE

Dear Colleagues and Friends of the Weinstein Community,

It is with great pleasure that we all welcome you to the **2024 Weinstein Cardiovascular Development and Regeneration Conference** in Montréal.

Settled 400 years ago, Montréal is also the place where Maude Abbott has developed the first classification of congenital heart disease in 1905, culminating with her famous atlas published in 1936. With this in mind, we are very honored to host the Weinstein meeting for the first time in Canada. Since the inaugural meeting, the Weinstein Conference has remained synonymous with the best science in the field, exciting discussions and an open exchange that favors young investigators. Over the years, a vast catalogue of seminal works has been presented and discussed at this meeting to allow a better understanding of heart formation, congenital cardiac defects and cardiac regeneration. In these decades, our field of research has been moving lightning fast. In parallel with progress in disruptive technologies, we can today ask questions and give answers that were unimaginable only a few years ago, to name just a few: progress in genomics, single cell biology, patient-specific models, microscopy and many others.

On Wednesday morning, before the start of the conference proper, you will have the choice between two excellent satellite meetings, one with a hands-on session on congenital heart disease specimens, with experts Lucile Houyel, MD, from Paris, France and Bjarke Jensen, PhD, from Amsterdam, The Netherlands, and additional instructors. Beyond the typical demonstration of three-dimensional anatomy, this session will also feature a unique species comparison. The second satellite symposium will focus on spatial transcriptomics, with a roster of excellent speakers also giving insight into this cutting edge technology and hands-on advice.

Also, we would like to welcome our keynote speakers Freda Miller, PhD, from UBC, Vancouver, and Christine Mummery, PhD, from Leiden University, The Netherlands. Dr. Miller has made critical discoveries in both the areas of neural stem cell biology and its contribution to psychiatric disease and the role of skin progenitor populations in homeostasis and mammalian digit tip regeneration. Dr. Mummery has pioneered the use of human pluripotent stem cells to study cardiovascular disease and regeneration, and to generate various organ-on-chip models. Her most recent work centres on safety pharmacology to predict toxic effects, individual vulnerability, and drug sensitivity.

We look forward to a stimulating program thanks to the talented young scientists who will once again share their research with our community and make the conference an exciting scientific time.

We hope you all enjoy your conference in Montreal,

CHU Sainte Justine and Hospital for Sick Children Planning Committee

Co-chairs:

Ian Scott, PhD

Senior Scientist, Developmental and Stem Cell Biology
Hospital for Sick Children
University of Toronto

Gregor Andelfinger, MD, FRCPC

Professor of Pediatrics
CHU Sainte Justine Research Center
Université de Montréal

Local Organizing Committee

Alexandre Dubrac, PhD

Associate Professor, Pathology and Cell Biology
CHU Sainte Justine Research Center
Université de Montréal

Rubén Marín Juez, PhD

Assistant Professor, Pathology and Cell Biology
CHU Sainte Justine Research Center
Université de Montréal

Piet van Vliet, PhD

Research Associate
CHU Sainte Justine Research Center
Université de Montréal

PARTNERS

DIAMOND

ADDITIONAL
VENTURES

SickKids
VS[®]

 **Fondation
CHU
Sainte-
Justine**


CIHR IRSC

10x
GENOMICS

 **BANQUE
NATIONALE**

PARTNERS

GOLD

illumina[®]

SILVER

Baylis *Advancing Technology.
Transforming Care.™*
MEDTECH

**DEV
BIO** SOCIETY FOR
DEVELOPMENTAL
BIOLOGY

BRONZE

 **Disease Models
& Mechanisms**

COLLABORATORS

 Oxford
NANOPORE
Technologies

**TOURISME /
MONTREAL**

KEYNOTE LECTURERS



Freda Miller

**University of British Columbia
Vancouver, Canada**

Dr. Freda Miller joined UBC from the Hospital for Sick Children in Toronto, where she was a Senior Scientist and Professor at the University of Toronto. Dr. Miller has carried out pioneering research in the areas of neural and epidermal stem cells and their contribution to development and regeneration. She is a Fellow of the Royal Society of Canada and of the

American Association for the Advancement of Science. While at the Hospital for Sick Children, she was a Howard Hughes Medical Institute International Research Scholar and the Canada Research Chair in Developmental Neurobiology. Most recently, Dr. Miller's accomplishments were recognized by the naming of the "Dr. Freda Miller" public school by the Calgary Board of Education.



Christine Mummery

**Leiden University Medical Center
Leiden, the Netherlands**

Dr. Christine Mummery is Professor of Developmental Biology at the Leiden University Medical Center, the Netherlands. Prof. Mummery has pioneered the use of human pluripotent stem cells to study cardiovascular disease and regeneration, to generate organ-on-chip models, and to investigate safety pharmacology. Prof. Mummery is a founding editor of the journal Stem Cell

Reports, and co-founded NCardia and the European Organ-on-Chip Society. She is a member of the Royal Netherlands Academy of Arts and Sciences and was president of the International Society for Stem Cell Research in 2020-2021. She received the Lefoulon Delalande Prize jointly with Gordon Keller in 2021 and the ISSCR Public Service Award in 2023.

ABOUT OUR PARTNERS:



Additional Ventures

Additional Ventures is a purpose-driven organization leveraging evidence-based research and deep subject matter expertise to make an outsized impact.

Contact: [Additional Ventures](#)



Canadian Institutes of Health Research (CIHR)

The Canadian Institutes of Health Research (CIHR) is Canada's federal funding agency for health research. Composed of 13 Institutes, we collaborate with partners and researchers to support the discoveries and innovations that improve our health and strengthen our health care system.



CHU Sainte-Justine Foundation

Since its beginnings, the Foundation has been engaging the community to make the CHU Sainte-Justine what it is today and what it will be tomorrow: a world-class university health centre that is building a healthier future for mothers and children.

Contact: [Sainte-Justine Foundation](#)



SickKids Foundation

SickKids Foundation believes that fighting for the health and wellbeing of children is one of the most powerful ways to improve society. And that starts with supporting the hospital. By fundraising in support of the hospital's Precision Child Health initiative, we are realizing our vision – we are healing the future.

Contact: [SickKids Foundation](#)

Video: [SickKids VS: Heal the future](#)

ABOUT OUR PARTNERS:



Baylis Medical Technologies

Baylis Medical Technologies seeks to improve the lives of patients through the conception and commercialization of state-of-the-art medical devices. The company proudly carries forward Gloria Baylis' legacy to enhance access to care through its divisions of Endovascular and Design and Manufacturing Services. Baylis Medical Technologies' clinical solutions are utilized by healthcare professionals worldwide to improve patient outcomes for individuals with cardiovascular and other medical conditions. Learn more about our innovative products and ongoing mission at www.baylismedtech.com.

Contact: [Baylis Medical Technologies](#)



10x Genomics

10x Genomics was founded on the vision that this century will bring advances in biomedicine and transform the way we understand and treat disease. We deliver powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Our end-to-end single cell and spatial solutions include instruments, consumables, and intuitive software, letting you unravel highly intricate biological systems, while bringing into focus the details that matter most.

Contact: [Patrick Lacasse](#), Sales Executive - Eastern Canada

Video: [10 years of innovation](#)

Learn more about: [Chromium X](#), [Visium HD](#), [Xenium](#), [Single Cell Gene Expression Flex](#), [Single Cell GEM-X](#)



Disease Models & Mechanisms

Disease Models & Mechanisms (DMM) is an Open Access biomedical research journal advancing novel insight into the mechanism, diagnosis and therapy of human disease. DMM is committed to publishing rigorously peer-reviewed research in disease biology that has significant translational impact at the interface of basic and clinical science. As well as primary research, we publish interviews, review and opinion articles from experts in the field.

Access our latest special issue '[Moving Heart Failure to Heart Success: Mechanisms, Regeneration & Therapy](#)' for free.

Contact: [Disease Models & Mechanisms](#)

Video: [Publishing in Disease Models & Mechanisms](#)

ABOUT OUR PARTNERS:



Illumina

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

Video: [Multiomics is changing the game - hear from researchers using it](#)

Social Media: [LinkedIn](#), [Facebook](#), [X](#), [Instagram](#)



Society for Developmental Biology

The Society for Developmental Biology employs an inclusive philosophy to further the study of developmental biology and related disciplines; to foster, support and provide a forum for all investigators in these fields; to educate non-specialists, educators, the general public and policy makers about developmental biology and related disciplines; and to promote fair, respectful, ethical and equitable practices throughout the scientific enterprise.

Contact: [Society for Developmental Biology](#)



Banque Nationale

The Banque Nationale Research Chair in Cardiovascular Genetics serves as the main incubator for research projects pertaining to cardiovascular diseases, including rare diseases or conditions, to help determine the as yet unknown causes of such diseases and ultimately help develop appropriate treatments. This chair helps maintain and broaden the cardiovascular disease tissue sample biobank.



Oxford Nanopore Technologies

Oxford Nanopore has developed a new generation of DNA/RNA sequencing technology. It is the only sequencing technology that offers real-time analysis (for rapid insights), in fully scalable formats from pocket to population scale, that can analyse native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths.

We're healing the **FUTURE** for Harper


Precision Child Health is a new approach to medicine at SickKids, tailored precisely to each unique patient: like Harper, who was born with a rare heart condition and received a heart transplant at age five.

At SickKids, we're leading the way in cardiac care: working to diagnose faster, treat smarter and predict better for more kids like Harper.

Join us to heal the future.

HealTheFuture.ca

SickKids
VS



LAND ACKNOWLEDGEMENT

We are coming here with respect for this land that we are on today, and for the people who have and do reside here. We acknowledge that Tiohtià:ke (*jo-ja-gay*) / Montréal is a place historically known as a gathering place for many First Nations. Let us celebrate life and beauty through what we do, and like generations before us have done on this land since times immemorial. We respect the continued connections with the past, present and future in our ongoing relationships with Indigenous and other peoples within the Montreal community.



WEINSTEIN CONFERENCE CHARTER

SCOPE OF THE CONFERENCE

The Weinstein Cardiovascular Development and Regeneration Conference is an annual, freestanding meeting unaffiliated with any society or parent organization. The meeting is designed for researchers investigating normal and abnormal development of the heart and vasculature, as well as regeneration of cardiovascular tissue. True to the vision of Dr. Constance Weinstein, who first organized this conference, the goal is to promote a collegiate environment for dissemination and discussion of innovative scientific findings, and encourage interactions and collaborations in order to improve patient outcome. A second important mission of the Weinstein Conference is to support and foster the next generation of scientists, including underrepresented minorities and women in the field.

The Weinstein committee

In order to provide continuity and maintain the quality of the conference, the participants of the 1998 meeting voted to form an organizing committee called the «Weinstein Committee». The makeup of the committee is composed of:

- a) A single representative from each of the three previous local organizing committees;
- b) A single member from the current host site local organizing committee. This person will serve as Chair of the Committee during the year prior to their meeting;
- c) A single representative from each of the next two proposed meeting sites;
- d) Two «At-Large» members, who are selected by a vote by the conference participants.

These committee members will serve a three-year term. Any institution should have a maximum of one member

serving on the Weinstein Committee at any given time. Committee members serve to assist the local organizing committee with conference arrangements, to help secure funding, and to solicit and vet nominations for future meeting sites and host institutions.

Hosting the annual Weinstein Conference

Interested individuals or groups from host institutions from within, and outside the USA organize the Weinstein meeting on a rotating, voluntary basis. Prospective host institutions should bid to host a future Weinstein meeting three years prior to the year that they desire to host the meeting. To do this, prospective host institutions should submit a preliminary application to the Weinstein Committee at least one month prior to bidding to host a future meeting. The preliminary application should contain details of:

- a) The prospective local organizing committee (see below). It is strongly encouraged that at least two Faculty are identified, per site, to support the meeting from bid stage;
- b) The prospective site for the meeting;
- c) A secure fundraising plan (institutional support and/or external support).

The purpose of early submission of a preliminary application is to allow the committee members to resolve any potential issues or missing details prior to presentation at the annual Weinstein meeting and vote at the annual business meeting.

The Weinstein Committee will evaluate all bids for feasibility to host the conference effectively in terms of fundraising and organizational and scientific capacity, and committee members will vote by proxy (led by The Chair of the Committee). Once approved by The Weinstein Committee, a maximum of three bids will be presented at the annual Weinstein meeting and put to vote the following day by all conference attendees at the annual business meeting.

Meeting sites will be selected by vote such that the future local organizing committee will have a three-year lead-time. The Weinstein Committee may solicit additional applications from prospective host institutions as needed. In the event that multi-year funding is sought from the National Institutes of Health or other national sources, the Weinstein Committee will participate in this process.

LOCAL ORGANIZING COMMITTEE

To provide a varied flavor and the opportunity for new, innovative themes in cardiovascular research, each host institution will form a local organizing committee that will be responsible for securing a meeting venue, developing a meeting program and fundraising to cover meeting expenses. In consideration of venue and program, the organizing committee should consider creating opportunities for informal communication and interaction, and minimize cost for attendees. In consideration of the program, the organizing committee are encouraged to support exposure of junior investigators, underrepresented minorities and women. This representation should occur at the level of the organizing committee, program chairs, and presenters.

OBLIGATIONS OF THE PARTICIPANTS

One of the most important aspects of the Weinstein Conference has been the willingness of the participants to share new and unpublished information. This has provided opportunities for the participants to devise new experiments

and develop new hypotheses in a collaborative manner. It is expected that all participants will participate in a collegial and ethical manner with respect to information obtained at the Weinstein Conference. Permission should be obtained before disclosure of another investigator's unpublished data.

Similarly, investigators pursuing similar experiments should inform a presenter if the divulged information has a bearing on their own work. All participants in the conference should be willing to share their expertise and reagents in the collective advancement of the area of cardiovascular development.

ANNUAL BUSINESS MEETING

Each Weinstein Conference will include time set aside for a business meeting and time for a subsequent vote on a future conference site by conference participants. At the Business Meeting, Weinstein Committee members may consider changes in the direction of the conference or its organization. At the 1999 meeting in Tucson, Arizona, an original Charter was distributed to the participants and ratified. The Charter was subsequently revised and updated following the 2011 Weinstein Meeting in Cincinnati and then ratified by the Weinstein Committee at the 2012 Weinstein Business Meeting in Chicago. Additional updates and modifications of the Weinstein Charter were made following the 2018 Weinstein Meeting in Nara, Japan and then ratified by the Weinstein Committee at the 2019 Weinstein Meeting in Indianapolis. The Charter will remain in effect until modified by a vote of the Weinstein Committee at the annual business meeting.

WEINSTEIN COMMITTEE AND HOSTS

WEINSTEIN COMMITTEE

Gregor Andelfinger and Ian Scott, co-organizers Weinstein 2024 (Gregor current chair, both off 2027)

Michaela Patterson, organizer Weinstein 2025, upcoming chair (off 2028)

Todd Evans, organizer Weinstein 2026 (off 2029)

Debbie Yelon, organizer Weinstein 2023 (off 2026)

Stéphan Zaffran, organizer Weinstein 2022 (off 2025)

Tony Firulli, organizer Weinstein 2019 (off 2024)

Nicole Dubois, elected at-large member (2023-26)

Sigolene Meilhac, elected at-large member (2022-25)

CONFERENCE CODE OF CONDUCT

This conference is supported in part a CIHR Planning and Dissemination grant. Additional support is provided by the Foundations of the Hospital for Sick Children, Toronto, Canada and CHU Sainte Justine, Montreal, Canada, as well as Banque Nationale. All conference sponsors strongly support the promotion of a safe and respectful conference environment.

ANTI-HARASSMENT POLICY

All conference sponsors strongly support the promotion of a safe and respectful conference environment. All attendees, speakers, sponsors and volunteers at our conference are required to agree with the following code of conduct. Organisers will enforce this code throughout the event. We expect cooperation from all participants to help ensure a safe environment for everybody.

Our conference is dedicated to providing a harassment-free conference experience for everyone, regardless of gender, gender identity and expression, age, sexual orientation, disability, physical appearance, body size, race, ethnicity, religion (or lack thereof), or technology choices. We do not tolerate harassment of conference participants in any form. Sexual language and imagery is not appropriate.

Harassment includes offensive verbal comments related to gender, gender identity and expression, age, sexual orientation, disability, physical appearance, body size, race, ethnicity, religion, technology choices, sexual images in public spaces, deliberate intimidation, stalking, following, harassing photography or recording, sustained disruption of talks or other events, inappropriate physical contact, and unwelcome sexual attention for any conference venue, including talks, workshops, social activities, X and other online media.

Sponsors are also subject to the anti-harassment policy. In particular, sponsors should not use sexualised images, activities, or other material. Booth staff (including volunteers) should not use sexualised clothing/uniforms/costumes, or otherwise create a sexualised environment.

Participants asked to stop any harassing behavior are expected to comply immediately.

If a participant engages in harassing behavior, the conference organisers may take any action they deem appropriate, including warning the offender or expulsion from the conference with no refund.

If you are being harassed, notice that someone else is being harassed, or have any other concerns, please contact a member of conference staff immediately. Conference staff will be happy to help participants contact hotel/venue security or local law enforcement, provide security guards, or otherwise assist those experiencing harassment to feel safe for the duration of the conference. We value your attendance.

We expect participants to follow these rules at conference and workshop venues and conference-related social events.

The background features a dark blue gradient with several light blue, curved, overlapping bands that suggest a cross-section of a blood vessel. A white catheter with a blue handle and a yellow tip is shown navigating through the vessel. A blue marker is also visible on the vessel wall.

CREATE A PATH FORWARD

Enable intervention with reliable crossing.

Baylis
MEDTECH

*Advancing Technology.
Transforming Care.™*

For more information visit www.baylismedtech.com

DETAILED PROGRAM

PLATFORM PRESENTATIONS



Weinstein
2024 | Montréal, Qc.

WEDNESDAY, MAY 15, 2024

PLATFORM SESSION 1: REGENERATION

Chair: Michaela Patterson, Medical College of Wisconsin, United States Of America

Fei Sun, Duke University, United States Of America

13:15 - 13:35 **CARDIOMYOCYTE REGENERATIVE POTENTIAL IN MAMMALS OF EXTREME LONGEVITY**

Xiaoxin Chen, University of California San Francisco, United States of America

Makoto Nakamura, Sheamin Khyeam, Alexander Y. Payumo, Jiajia Wang, Hongyao Yu, Xiaochen Zhong, Vassily Kutuyavin, Alison Hoang, Kentaro Hirose, Xi Chen, Nevan Powers, Joseph Moreno, Simon Bucher, William Yue, Bruce Wang, Brian Woo, Hani Goodarzi, Hao Wu, Yifan Cheng, Junjiao Yang, Xiaokun Shu, Richard Seymour, Alexia Kirby, Adam Shuhendler, Bogdan Kirilenko, Michael Hiller, Rochelle Buffenstein, Matthew Vickaryous, Guang Hu, Matthew Pamenter, Guo N. Huang

13:35 - 13:55 **THE INDISPENSABLE ROLE CD36⁺-TISSUE RESIDENT MACROPHAGES IN CARDIAC REGENERATION**

Yen Ling Hung, Graduate Institute of Pharmacology, National Taiwan University, Taiwan (Republic of China)

Kuan-Yu Liu, Chen-Ting Hung, Kai-Chien Yang

13:55 - 14:15 **HARNESSING THE REGENERATIVE POTENTIAL OF INTERLEUKIN11 TO ENHANCE HEART REPAIR**

Kwangdeok Shin, University of Wisconsin-Madison, United States of America

Anjelica Rodriguez-Parks

14:15 - 14:35 **STABILISATION OF HIF SIGNALLING IN THE EPICARDIUM EXTENDS EMBRYONIC POTENTIAL AND NEONATAL HEART REGENERATION AND IMPROVES ADULT REPAIR**

Elisabetta Gamen, University of Oxford, United Kingdom

Eleonor L. Proce, Daniela Pezzolla, Carla De Villiers, Mala Gunadasa-Rohling, Rafik Salama, Adam Lokman, Maria-Alexa Cosma, Judith Sayers, David Mole, Tammie Bishop, Christopher Pugh, Robin Choudhury, Carolyn Carr, Joaquim Miguel Vieira, Paul Riley

14:35 - 14:55 **WHOLE-BODY TRACKING OF ENHANCER-DIRECTED, INJURY-TARGETING GENE THERAPY VECTORS**

David Wolfson, Duke University, United States of America

Kelsey Oonk, Garth Devlin, Thomas Dvergsten, Valentina Cigliola, Aravind Asokan, Kenneth Poss

14:55 - 15:15 **CARDIAC AXOL-OMICS: SPATIAL TRANSCRIPTOMIC ANALYSIS OF AXOLOTL CARDIAC REGENERATION**

Elad Bassat, Research Institute of Molecular Pathology (IMP), Austria

PLATFORM SESSION 2: CARDIAC CONDUCTION AND ELECTROPHYSIOLOGY

Chair: Michelle Collins, University of Saskatchewan, Canada

Vincent Christoffels, Amsterdam University Medical Centers, Netherlands

15:40 - 16:00 **LEFT-RIGHT DIFFERENCES IN WNT INHIBITION UNDERLIE A PRO-FIBROTIC MICROENVIRONMENT AND ATRIAL FIBRILLATION PREDISPOSITION FOR PITX2 DEFICIENCY**

Jeffrey Steimle, Baylor College of Medicine, United States of America

Zachary Kadow, Matthew Hill, Xiao Li, Ge Tao, James Martin

16:00 - 16:20 **RADIATION MEDIATED CARDIOMYOCYTE REPROGRAMMING: INSIGHTS INTO MECHANISMS OF CARDIAC RADIOTHERAPY FOR VENTRICULAR TACHYCARDIA**

Samuel Jordan, Washington University School of Medicine, United States of America

Jeffrey Szymanski, Sherwin Ng, David Zhang, Sneha Manikandan, Lei Huang, Lori Strong, Stephanie Hicks, James Tabor, Anish Bedi, Lavanya Aryan, Lauren Boggs, Kuo-Chan Weng, Nathaniel Huebsch, Julie Schwarz, Stacey Rentschler

16:20 - 16:40 **THE PACEMAKER TRIO: EPICARDIAL - NEURONAL - MYOCARDIAL INTERACTIONS DURING ZEBRAFISH PACEMAKER DEVELOPMENT**

Annika Nürnberg, Max Planck Institute for Heart and Lung Research, Germany

Marga Albu, Mridula Balakrishnan, Didier Stainier

16:40 - 17:00 **HUMAN INDUCED PLURIPOTENT STEM CELLS' MODEL OF LMNA-RELATED CARDIOMYOPATHY**

Hananeh Fonoudi, Northwestern University, United States of America

Ali Negahi Shirazi, Hui-Hsuan Kuo, Carlos G. Vanoye, Xiaozhi Gao, Mariam Jouni, Brian Lenny, Achal Neupane, Janavi Kotamarthi, Yadav Sapkota, Jane E. Wilcox, Alfred L. Jr. George, Paul W. Burridge
